Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move.
Here’s a look at the top five short squeeze candidates for the week of Sept. 12, according to Fintel Data: